Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 3 | 2019 | 86 | 0.800 |
Why?
|
| Doxycycline | 1 | 2022 | 49 | 0.780 |
Why?
|
| Gastric Mucosa | 1 | 2022 | 77 | 0.780 |
Why?
|
| Esophagitis | 1 | 2019 | 45 | 0.640 |
Why?
|
| Steroids | 1 | 2019 | 84 | 0.620 |
Why?
|
| Splenosis | 1 | 2017 | 4 | 0.600 |
Why?
|
| Esophagus | 1 | 2019 | 303 | 0.570 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 163 | 0.520 |
Why?
|
| Liver | 3 | 2017 | 1118 | 0.510 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 334 | 0.460 |
Why?
|
| Liver Transplantation | 5 | 2022 | 400 | 0.360 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2012 | 27 | 0.350 |
Why?
|
| Biopsy | 2 | 2022 | 540 | 0.300 |
Why?
|
| Hepacivirus | 2 | 2019 | 90 | 0.270 |
Why?
|
| Protein C Deficiency | 1 | 2005 | 5 | 0.250 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2005 | 11 | 0.250 |
Why?
|
| Antiviral Agents | 2 | 2019 | 211 | 0.240 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 125 | 0.230 |
Why?
|
| Glucuronates | 2 | 2012 | 19 | 0.210 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 805 | 0.210 |
Why?
|
| Liver Diseases | 3 | 2014 | 193 | 0.210 |
Why?
|
| Stomach | 1 | 2022 | 80 | 0.200 |
Why?
|
| Prednisone | 2 | 2019 | 104 | 0.180 |
Why?
|
| Esophagoscopy | 2 | 2019 | 72 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2010 | 37 | 0.160 |
Why?
|
| Methylprednisolone | 1 | 2019 | 99 | 0.160 |
Why?
|
| Liver Cirrhosis | 4 | 2014 | 301 | 0.150 |
Why?
|
| Humans | 20 | 2022 | 68618 | 0.150 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1140 | 0.140 |
Why?
|
| Male | 15 | 2019 | 37321 | 0.140 |
Why?
|
| Aged | 6 | 2019 | 14862 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 297 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 1026 | 0.120 |
Why?
|
| Glycerophospholipids | 1 | 2014 | 20 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 511 | 0.110 |
Why?
|
| Heart Failure | 1 | 2022 | 1180 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2223 | 0.110 |
Why?
|
| Sulfuric Acid Esters | 1 | 2012 | 7 | 0.100 |
Why?
|
| Hair | 1 | 2012 | 46 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 60 | 0.100 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2003 | 47 | 0.100 |
Why?
|
| Analgesics | 1 | 2012 | 118 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 2 | 2010 | 30 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2012 | 110 | 0.090 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.090 |
Why?
|
| Mandibular Diseases | 1 | 2010 | 28 | 0.090 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2010 | 22 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 24 | 0.090 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 62 | 0.090 |
Why?
|
| Melanoma | 1 | 2013 | 335 | 0.080 |
Why?
|
| Middle Aged | 11 | 2019 | 21147 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 514 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 375 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2008 | 58 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2013 | 7029 | 0.070 |
Why?
|
| Adult | 11 | 2019 | 21403 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2008 | 237 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1070 | 0.060 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 10 | 0.060 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2005 | 37 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1753 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2005 | 97 | 0.060 |
Why?
|
| Female | 12 | 2019 | 38074 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 649 | 0.060 |
Why?
|
| Bile Duct Diseases | 1 | 2003 | 28 | 0.060 |
Why?
|
| Esophagoscopes | 1 | 2003 | 5 | 0.060 |
Why?
|
| Electric Power Supplies | 1 | 2003 | 26 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 78 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2005 | 356 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 102 | 0.050 |
Why?
|
| Biliary Tract Diseases | 1 | 2001 | 50 | 0.050 |
Why?
|
| Heart Atria | 1 | 2022 | 206 | 0.050 |
Why?
|
| Pancreatic Diseases | 1 | 2001 | 66 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2001 | 57 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2002 | 171 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2008 | 1615 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2019 | 4 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 11 | 0.040 |
Why?
|
| Sofosbuvir | 1 | 2019 | 16 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 45 | 0.040 |
Why?
|
| Ribavirin | 1 | 2019 | 27 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 78 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 705 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 515 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 216 | 0.040 |
Why?
|
| Stents | 1 | 2003 | 657 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 304 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 141 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2019 | 128 | 0.040 |
Why?
|
| Biomarkers | 2 | 2014 | 1593 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 786 | 0.040 |
Why?
|
| Alcoholism | 1 | 2005 | 1109 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 2279 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 4848 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2324 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1851 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2012 | 7277 | 0.030 |
Why?
|
| Time Factors | 3 | 2008 | 4655 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2013 | 10 | 0.030 |
Why?
|
| Viral Load | 1 | 2013 | 127 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 2012 | 66 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 392 | 0.020 |
Why?
|
| Prognosis | 2 | 2007 | 2093 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 319 | 0.020 |
Why?
|
| Azathioprine | 1 | 2010 | 16 | 0.020 |
Why?
|
| Virus Activation | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 27 | 0.020 |
Why?
|
| Gingival Diseases | 1 | 2010 | 22 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 33 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2010 | 22 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 36 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 55 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 111 | 0.020 |
Why?
|
| Prevalence | 2 | 2007 | 1619 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Rituximab | 1 | 2010 | 61 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1553 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1330 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2003 | 348 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1465 | 0.020 |
Why?
|
| Hemangioma | 1 | 2008 | 51 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 79 | 0.020 |
Why?
|
| Cysts | 1 | 2008 | 70 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 214 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 780 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 245 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2005 | 114 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 306 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.010 |
Why?
|
| Duodenoscopes | 1 | 2003 | 7 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2003 | 104 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2003 | 236 | 0.010 |
Why?
|
| Adolescent | 2 | 2007 | 8912 | 0.010 |
Why?
|
| South Carolina | 1 | 2008 | 2752 | 0.010 |
Why?
|
| Registries | 1 | 2005 | 733 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 500 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 1038 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 652 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1603 | 0.010 |
Why?
|
| Physician's Role | 1 | 2001 | 116 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 2891 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 546 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 3187 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 2358 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2001 | 383 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 2007 | 0.010 |
Why?
|
| Logistic Models | 1 | 2002 | 1420 | 0.010 |
Why?
|
| Decision Making | 1 | 2001 | 410 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5731 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 3259 | 0.010 |
Why?
|
| Child | 1 | 2007 | 6405 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1196 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 3705 | 0.010 |
Why?
|